Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors
Ankyra has appointed Dr. Julia G. Butchko and Ms. Tara Withington as independent board members, effective September 25, 2024. This brings the total board composition to seven directors. Dr. Butchko, with 25 years of industry experience, most recently served as Chief Development Officer at Immunovant (NASDAQ: IMVT). Ms. Withington has over 40 years of executive experience in the nonprofit sector and is currently a principal and Vice President with Executive Director, Incorporated (EDI).
Ankyra's lead asset, ANK-101, an anchored IL-12, has entered phase I clinical trials earlier this year. Over 10 patients with advanced solid cancers have been treated at multiple study sites in the United States and Canada (NCT:06171750).
Ankyra ha nominato la Dott.ssa Julia G. Butchko e la Signora Tara Withington come membri indipendenti del consiglio, a partire dal 25 settembre 2024. Questo porta la composizione totale del consiglio a sette direttori. La Dott.ssa Butchko, con 25 anni di esperienza nel settore, ha recentemente ricoperto il ruolo di Chief Development Officer presso Immunovant (NASDAQ: IMVT). La Signora Withington ha oltre 40 anni di esperienza dirigenziale nel settore nonprofit ed attualmente è un principale e Vicepresidente presso Executive Director, Incorporated (EDI).
Il principale attivo di Ankyra, ANK-101, un IL-12 ancorato, ha iniziato la fase I degli studi clinici all'inizio di quest'anno. Oltre 10 pazienti con tumori solidi avanzati sono stati trattati in più sedi di studio negli Stati Uniti e in Canada (NCT:06171750).
Ankyra ha nombrado a la Dra. Julia G. Butchko y la Sra. Tara Withington como miembros independientes de la junta, con efecto a partir del 25 de septiembre de 2024. Esto lleva el total de la composición de la junta a siete directores. La Dra. Butchko, con 25 años de experiencia en la industria, se desempeñó recientemente como Jefa de Desarrollo en Immunovant (NASDAQ: IMVT). La Sra. Withington tiene más de 40 años de experiencia ejecutiva en el sector sin fines de lucro y actualmente es principal y Vicepresidenta de Executive Director, Incorporated (EDI).
El activo principal de Ankyra, ANK-101, un IL-12 anclado, ha entrado en ensayos clínicos de fase I a principios de este año. Más de 10 pacientes con cánceres sólidos avanzados han sido tratados en múltiples sitios de estudio en Estados Unidos y Canadá (NCT:06171750).
ANKYRA는 Dr. Julia G. Butchko와 Tara Withington씨를 독립 이사로 임명하였으며, 이는 2024년 9월 25일부터 시행됩니다. 이로써 이사회의 총 구성원은 7명으로 늘어났습니다. Butchko 박사는 25년의 산업 경험을 갖추고 있으며, 최근에는 Immunovant(NASDAQ: IMVT)에서 최고 개발 책임자로 근무하였습니다. Withington 씨는 비영리 부문에서 40년 이상의 임원 경험을 가지고 있으며, 현재 Executive Director, Incorporated (EDI)에서 주요 담당자 및 부사장으로 재직 중입니다.
ANKYRA의 주요 자산인 ANK-101, 고정 IL-12는 올해 초에 1상 임상 시험에 들어갔습니다. 미국과 캐나다의 여러 연구 사이트에서 10명 이상의 진행성 고형암 환자가 치료받았습니다 (NCT:06171750).
Ankyra a nommé Dr. Julia G. Butchko et Mme Tara Withington comme membres indépendants du conseil d'administration, à compter du 25 septembre 2024. Cela porte la composition totale du conseil à sept directeurs. Dr. Butchko, avec 25 ans d'expérience dans l'industrie, a récemment occupé le poste de Chief Development Officer chez Immunovant (NASDAQ: IMVT). Mme Withington a plus de 40 ans d'expérience exécutive dans le secteur à but non lucratif et est actuellement principale et vice-présidente chez Executive Director, Incorporated (EDI).
L'actif principal d'Ankyra, ANK-101, un IL-12 ancré, a commencé les essais cliniques de phase I plus tôt cette année. Plus de 10 patients atteints de cancers solides avancés ont été traités sur plusieurs sites d'étude aux États-Unis et au Canada (NCT:06171750).
Ankyra hat Dr. Julia G. Butchko und Ms. Tara Withington zu unabhängigen Vorstandsmitgliedern ernannt, mit Wirkung zum 25. September 2024. Damit erhöht sich die Gesamtzahl der Vorstandsmitglieder auf sieben. Dr. Butchko bringt 25 Jahre Branchenerfahrung mit und war zuletzt Chief Development Officer bei Immunovant (NASDAQ: IMVT). Ms. Withington hat über 40 Jahre Erfahrung in Führungsrollen im Non-Profit-Sektor und ist derzeit Hauptverantwortliche und Vizepräsidentin bei Executive Director, Incorporated (EDI).
Das Hauptvermögen von Ankyra, ANK-101, ein verankertes IL-12, hat Anfang dieses Jahres in die Phase-I-Studien begonnen. Über 10 Patienten mit fortgeschrittenen soliden Tumoren wurden an mehreren Studienstandorten in den USA und Kanada behandelt (NCT:06171750).
- Appointment of two experienced independent board members, potentially bringing fresh perspectives and expertise
- ANK-101 has entered phase I clinical trials with over 10 patients treated
- Expansion of clinical trial sites to multiple locations in the US and Canada
- None.
Julia G. Butchko, Ph.D. brings 25 years of industry experience and most recently served as Chief Development Officer at Immunovant (NASDAQ: IMVT), a biopharmaceutical company focused on developing therapies for patients with autoimmune disease. Dr. Butchko joined Immunovant in October 2019 and has co-led Research and Development to advance batoclimab (IMVT-1401) from early development to multiple, global registration trials and IMVT-1402 from candidate identification through registration trial planning. Prior to Immunovant, Dr. Butchko held various leadership roles at Eli Lilly and Company where she most recently served as the Chief of Staff, Strategy and Operations for Lilly’s Immunology and Neuroscience businesses and Vice President, Lilly Oncology Portfolio Management and Clinical Development. Dr. Butchko earned a B.S. in Chemistry from the State University of
Tara Withington has over 40 years’ executive experience serving the nonprofit sector. Currently she is a principal and Vice President with Executive Director, Incorporated (EDI), an association management company that manages more than 40 scientific organizations and professional boards. She takes special interest in improving organizational excellence, including board development and infrastructure improvement. She also has a keen ability to forecast influences impacting associations and offers innovative ideas and an entrepreneurial mindset to position organizations to take advantage of opportunities and identify challenges allowing organizations to pivot for optimal outcomes. She has previously served as executive director or consulting partner for over 20 organizational boards. Ms. Withington served as a member of the Board of Directors for the AMC Institute and is a member in good standing in the American Society of Association Executives (ASAE), where she currently serves as a member of the Foresight Advisory Task Force. In 2001, the Society for Immunotherapy of Cancer (SITC) joined EDI and Ms. Withington began her tenure as the Executive Director and principal staff member. Tara has been instrumental in positioning the society as a universally respected organization known for its dedication to advancing the science and application of cancer immunotherapy both in the US and abroad. Ms. Withington holds a degree in Business Management as well as the Certified Association Executive (CAE) designation. In 2020 she received the Society for Immunotherapy of Cancer inaugural Lifetime Achievement Award. She currently serves as the Executive Director Emeritus of SITC Ms. Withington states “I am especially pleased to be joining the Board at Ankyra at this exciting time in their development.” She added that immunotherapy “offers a chance for durable responses and better patient experience, and I share the Ankyra team’s vision of providing new drugs for patients with cancer while ensuring broad access to the drug for patients who may benefit.”
Dr. Howard L. Kaufman, President and CEO at Ankyra added “I am delighted to welcome Dr. Butchko and Ms. Withington to the Ankyra Board of Directors. They bring valuable expertise to the company and will add diversity and new perspectives on our goal of advancing the research and development of our anchoring platform and our commitment to doing so in a patient-focused manner.” Ankyra’s lead asset, ANK-101, is an anchored IL-12 that entered phase I clinical trials earlier this year and now over 10 patients with advanced solid cancers have been treated at multiple study sites in
About Ankyra Therapeutics
Ankyra Therapeutics is a biotechnology company that has developed a highly differentiated technology platform that expands the therapeutic window of cytokine drugs by forming a stable depot in the tumor after local administration leading to prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity. Ankyra was founded in 2019 and is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923495721/en/
For Investor Inquiries:
Howard L. Kaufman, MD
President and CEO
Ankyra Therapeutics
info@ankyratx.com
For Media Inquiries:
Noah Oshry
Head of Business Operations
noshry@ankyratx.com
Source: Ankyra Therapeutics
FAQ
Who are the new board members appointed by Ankyra?
What is Ankyra's lead asset and its current development stage?
How many patients have been treated with ANK-101 in the clinical trials?
What is the clinical trial identifier for Ankyra's ANK-101 study?
